The vector of anti-CD19 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD19. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD19 antibody linked to FcεRIγ signaling domains. And the vector product was designed for the treatment of chronic lymphoid leukemia.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|VP-CAR-LC522||Lenti-CD19 CAR (scFv-CD28-CD27-FcεRIγ, FMC63) Viral Particle|
|CAR-LC016||Anti-CD19 (FMC63) h(CD28-CD27-FcεRIγ) CAR, pCDCAR1|
|CAR-LC298||Anti-CD19 (4G7) h(41BB) Multi-chain CAR, pCDCAR1|
|VP-CAR-LC704||Lenti-CD19 CAR (scFv-41BB-CD3ζ, S2) Viral Particle|
|CAR-LC350||Anti-CD19 (Blinatumomab) h(CD28-CD3ζ, EGFRt) Marked CAR, pCDCAR1|
|VP-CAR-LC62||Lenti-CD19 CAR (scFv-FcεRIγ, FMC63) Viral Particle|
|CAR-LC348||Anti-CD19 (FMC63) h(41BB-CD3ζ, Strep Tag) Marked CAR, pCDCAR1|
|CAR-LC013||Anti-CD19 (47G4) h(41BB-CD27-CD3ζ) CAR, pCDCAR1|
|CAR-LC184||Anti-CD19 (Coltuximab) h(CD3ζ) CAR, pCDCAR1|
|CAR-T-3-L332-2BZ||Anti-CD19 scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1|
Copyright © 2007 - 2018 Creative Biolabs. All Rights Reserved